P J McElnay1, A Choong2, E Jordan3, F Song4, E Lim5. 1. Department of Cardiothoracic Surgery, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK. 2. Specialty Registrar in Vascular Surgery, Imperial College Healthcare NHS Trust, London, UK. 3. Library Services, University Hospitals Bristol NHS Foundation Trust, Bristol, UK. 4. Faculty of Health, University of East Anglia, Norwich, UK. 5. Imperial College London and The Academic Division of Thoracic Surgery, Royal Brompton Hospital, London, UK.
Abstract
OBJECTIVE: Chemoradiotherapy is often considered the 'standard of care' for patients with N2 disease. The aim was to evaluate survival outcomes of patients with N2 disease in multimodality trials of chemotherapy, radiotherapy and surgery. METHODS: Systematic review and meta-analyses (random and fixed effects) were performed. Searches of Medline and Embase (1980-2013) were conducted. Abstracts from thoracic scientific meetings were searched. Reference lists of all relevant studies were reviewed. All studies of patients with N2 disease who received induction chemotherapy or chemoradiotherapy and randomised to surgery or radiotherapy were included. No language restrictions were imposed. The main outcome was overall survival. RESULTS: 805 publications were identified. 519 and 281 were excluded because they were not primary results from randomised trials (or did not include N2 disease) or did not compare surgery with radiotherapy, respectively. The final six trials consisted of 868 patients. In four trials, patients received induction chemotherapy and in two trials patients received induction chemoradiotherapy. The HR comparing patients randomised to surgery after chemotherapy was 1.01 (95% CI 0.82 to 1.23; p=0.954) whereas for patients randomised to surgery after chemoradiotherapy was 0.87 (0.75 to 1.01; p=0.068). The overall HR of all pooled trials was 0.92 (0.81 to 1.03; p=0.157). CONCLUSIONS: Surgery should be considered as part of multimodality treatment for patients with resectable lung cancer and ipsilateral mediastinal nodal disease. In trials where patients received surgery as part of trimodality treatment, overall survival was better than chemoradiotherapy alone. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: Chemoradiotherapy is often considered the 'standard of care' for patients with N2 disease. The aim was to evaluate survival outcomes of patients with N2 disease in multimodality trials of chemotherapy, radiotherapy and surgery. METHODS: Systematic review and meta-analyses (random and fixed effects) were performed. Searches of Medline and Embase (1980-2013) were conducted. Abstracts from thoracic scientific meetings were searched. Reference lists of all relevant studies were reviewed. All studies of patients with N2 disease who received induction chemotherapy or chemoradiotherapy and randomised to surgery or radiotherapy were included. No language restrictions were imposed. The main outcome was overall survival. RESULTS: 805 publications were identified. 519 and 281 were excluded because they were not primary results from randomised trials (or did not include N2 disease) or did not compare surgery with radiotherapy, respectively. The final six trials consisted of 868 patients. In four trials, patients received induction chemotherapy and in two trials patients received induction chemoradiotherapy. The HR comparing patients randomised to surgery after chemotherapy was 1.01 (95% CI 0.82 to 1.23; p=0.954) whereas for patients randomised to surgery after chemoradiotherapy was 0.87 (0.75 to 1.01; p=0.068). The overall HR of all pooled trials was 0.92 (0.81 to 1.03; p=0.157). CONCLUSIONS: Surgery should be considered as part of multimodality treatment for patients with resectable lung cancer and ipsilateral mediastinal nodal disease. In trials where patients received surgery as part of trimodality treatment, overall survival was better than chemoradiotherapy alone. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Lung Cancer; Lung Cancer Chemotherapy; Thoracic Surgery
Authors: Gaetano Rocco; Katie Nason; Alex Brunelli; Gonzalo Varela; Thomas Waddell; David R Jones Journal: Eur J Cardiothorac Surg Date: 2016-04 Impact factor: 4.191
Authors: Chi-Fu Jeffrey Yang; Syed M Adil; Kevin L Anderson; Robert Ryan Meyerhoff; Ryan S Turley; Matthew G Hartwig; David H Harpole; Betty C Tong; Mark W Onaitis; Thomas A D'Amico; Mark F Berry Journal: Eur J Cardiothorac Surg Date: 2015-12-30 Impact factor: 4.191
Authors: Paul E Van Schil; Lawek Berzenji; Suresh K Yogeswaran; Jeroen M Hendriks; Patrick Lauwers Journal: Front Oncol Date: 2017-10-26 Impact factor: 6.244
Authors: Sahar Mokhles; Fergus Macbeth; Tom Treasure; Riad N Younes; Robert C Rintoul; Francesca Fiorentino; Ad J J C Bogers; Johanna J M Takkenberg Journal: Eur J Cardiothorac Surg Date: 2017-06-01 Impact factor: 4.191
Authors: Hari B Keshava; Kay See Tan; Joseph Dycoco; Jennifer Livschitz; Matthew J Bott; James Huang; Valerie W Rusch; James M Isbell; Daniela Molena; Manjit S Bains; David R Jones; Gaetano Rocco Journal: Semin Thorac Cardiovasc Surg Date: 2020-08-25